Clinical Trial Update: Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating the combination of pembrolizumab and sacituzumab govitecan for high-risk, localized muscle-invasive bladder cancer, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Urothelial Carcinoma of the Bladder

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: Claudia Guerrieri | Conditions: Muscle-invasive Urothelial Carcinoma of the Bladder | Phase 2 | Status: ACTIVE_NOT_RECRUITING